Abiraterone acetate

Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598) .

Product Specifications

CAS Number

[154229-18-2]

Product Name Alternative

CB7630

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Cytochrome P450

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Abiraterone-acetate.html

Concentration

10mM

Purity

99.91

Solubility

DMSO : 10 mg/mL (ultrasonic)

Smiles

O=C(O[C@@H]1CC2=CC[C@]3([H])[C@]([H])(CC[C@](C)(C(C4=CN=CC=C4)=CC5)[C@]35[H])[C@@]2(C)CC1)C

Molecular Formula

C26H33NO2

Molecular Weight

391.55

Precautions

H302, H315, H319, H335

References & Citations

[1]Stein MN, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl. 2014 May-Jun;16 (3) :387-400.|[2]Richards J, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012 May 1;72 (9) :2176-82.|[3]Li R, et al. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res. 2012 Jul 1;18 (13) :3571-9.|[4]Lee GT, et al. Intracrine androgen biosynthesis in renal cell carcinoma. Br J Cancer. 2017 Mar 28;116 (7) :937-943.|[5]A O'Donnell, et al. Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. British Journal of Cancervolume 90, pages2317–2325 (2004)